Novozymes A/S Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Novozymes A/S Stock Forecast and Price Target
If the average price target of kr435.00 set by four distinguished experts for Novozymes A/S over the past few weeks is reached this year, there would be a potential upside of approximately 13.67% from the last closing price in April, 2024. This potential increase is based on a high estimate of kr500.00 and a low estimate of kr350.00. If you want to invest in NZYM B stock, you might also want to take a look at how its competitors are doing.
13.67% Upside
Novozymes A/S Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Novozymes A/S's Price has decreased by 100.00%, going from kr313.33 to kr0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach kr421.21 – an increase of 100.00%. Over the next nine years, experts anticipate that Fair Value growth for Novozymes A/S will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NESN Stock Forecast | Nestlé | Outperform |
11
|
CHF93.24 | Buy/Sell | CHF115.58 | 17.98% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.39 | Buy/Sell | $32.87 | 20.13% |
| BAS Stock Forecast | BASF | Outperform |
12
|
51.07€ | Buy/Sell | 49.50€ | 9.65% |
| BN Stock Forecast | Danone | Outperform |
11
|
59.06€ | Buy/Sell | 55.47€ | 8.36% |
| GIVN Stock Forecast | Givaudan | Hold |
14
|
CHF3.90k | Buy/Sell | CHF3.14k | -1.33% |
Novozymes A/S Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Novozymes A/S has grown by 27.74%, going from kr14.01B to kr17.90B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach kr18.84B – an increase of 5.28%. Over the next seven years, experts anticipate that Revenue growth for Novozymes A/S will be 42.48%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GIS Stock Forecast | General Mills Inc | Hold |
18
|
$69.09 | Buy/Sell | $68.63 | 4.21% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$53.96 | Buy/Sell | $61.72 | 18.61% |
| DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$73.53 | Buy/Sell | $75.38 | 8.80% |
.jpg)
Novozymes A/S Dividend per Share Forecast for 2023 - 2025 - 2030
Novozymes A/S's Dividend per Share has grown in the last two years, jumping from kr5.25 to kr6.00 – an increase of 14.29%. In the next year, analysts predict that Dividend per Share will reach kr6.48 – an increase of 8.00%. For the next eight years, the forecast is for Dividend per Share to grow by 92.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DSFIR Stock Forecast | DSM-Firmenich | Outperform |
18
|
102.75€ | Buy/Sell | 114.60€ | 16.79% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.24€ | Buy/Sell | 45.15€ | 21.95% |
| IFF Stock Forecast | International Flavors & Fragra... | Hold |
15
|
$83.60 | Buy/Sell | $84.46 | 4.07% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MKC Stock Forecast | McCormick & Company | Hold |
12
|
$72.70 | Buy/Sell | $72.03 | 3.16% |
| K Stock Forecast | Kellanova | Hold |
13
|
$56.54 | Buy/Sell | $59.19 | 4.35% |
| EMSN Stock Forecast | EMS-CHEMIE HOLDING | Hold |
18
|
CHF690.00 | Buy/Sell | CHF657.14 | -7.68% |
Novozymes A/S EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Novozymes A/S's EBITDA has grown, increasing from kr4.72B to kr5.63B – an increase of 19.35%. For next year, the 13 analysts predict EBITDA of kr6.45B, which would mean an increase of 14.54%. Over the next seven years, the pros' prediction is EBITDAof kr9.23B, which would mean a seven-year growth forecast of 63.83%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SY1 Stock Forecast | Symrise | Outperform |
18
|
103.60€ | Buy/Sell | 106.97€ | 9.07% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$12.78 | Buy/Sell | $11.59 | 25.20% |
| KRZ Stock Forecast | Kerry Group | Outperform |
18
|
79.05€ | Buy/Sell | 96.27€ | 25.87% |
Novozymes A/S EBIT Forecast for 2023 - 2025 - 2030
Novozymes A/S's EBIT has increased by 21.18% In the last three years, going from kr3.68B to kr4.46B. In the next year, analysts expect EBIT to reach kr4.89B – an increase of 9.59%. For the next seven years, the forecast is for EBIT to grow by 63.08%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALB Stock Forecast | Albemarle | Outperform |
11
|
$111.80 | Buy/Sell | $154.93 | 29.70% |
| AKZA Stock Forecast | Akzo Nobel N.V. | Outperform |
18
|
66.10€ | Buy/Sell | 79.42€ | 17.25% |
| EMN Stock Forecast | Eastman Chemical Co | Outperform |
11
|
$96.02 | Buy/Sell | $96.03 | 5.19% |
Novozymes A/S EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Novozymes A/S's EPS has decreased by 100.00%, going from kr10.02 to kr0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach kr13.47 – an increase of 100.00%. Over the next nine years, experts anticipate that EPS growth for Novozymes A/S will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CHR Stock Forecast | Chr. Hansen Holding A/S | - |
16
|
kr549.60 | Buy/Sell | kr71.11 | -100.00% |
| EVK Stock Forecast | Evonik Industries | Outperform |
18
|
19.27€ | Buy/Sell | 20.64€ | 3.79% |
| BARN Stock Forecast | Barry Callebaut | Outperform |
18
|
CHF1.39k | Buy/Sell | CHF1.88k | 14.78% |
.jpg)